These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31384314)

  • 1. Update on novel pharmacological therapies for osteoarthritis.
    Ghouri A; Conaghan PG
    Ther Adv Musculoskelet Dis; 2019; 11():1759720X19864492. PubMed ID: 31384314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects for Therapies in Osteoarthritis.
    Ghouri A; Conaghan PG
    Calcif Tissue Int; 2021 Sep; 109(3):339-350. PubMed ID: 32055890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
    Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
    Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating osteoarthritis pain: recent approaches using pharmacological therapies.
    Ghouri A; Conaghan PG
    Clin Exp Rheumatol; 2019; 37 Suppl 120(5):124-129. PubMed ID: 31621576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A brief review of current treatment options for osteoarthritis including disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics.
    Jiang P; Hu K; Jin L; Luo Z
    Ann Med Surg (Lond); 2024 Jul; 86(7):4042-4048. PubMed ID: 38989236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Models for Development of Disease-Modifying Osteoarthritis Drugs.
    Makarczyk MJ; Gao Q; He Y; Li Z; Gold MS; Hochberg MC; Bunnell BA; Tuan RS; Goodman SB; Lin H
    Tissue Eng Part C Methods; 2021 Feb; 27(2):124-138. PubMed ID: 33403944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine?
    Roubille C; Pelletier JP; Martel-Pelletier J
    Expert Opin Pharmacother; 2013 Oct; 14(15):2059-77. PubMed ID: 24044485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in osteoarthritis pharmacological therapies.
    Ghouri A; Quicke JG; Conaghan PG
    Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi1-vi11. PubMed ID: 34951922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latest insights in disease-modifying osteoarthritis drugs development.
    Li S; Cao P; Chen T; Ding C
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231169839. PubMed ID: 37197024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Trends in Pharmacological Treatments for Osteoarthritis.
    Cai X; Yuan S; Zeng Y; Wang C; Yu N; Ding C
    Front Pharmacol; 2021; 12():645842. PubMed ID: 33935742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions.
    Cho Y; Jeong S; Kim H; Kang D; Lee J; Kang SB; Kim JH
    Exp Mol Med; 2021 Nov; 53(11):1689-1696. PubMed ID: 34848838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Treatment Options for Osteoarthritis.
    Hermann W; Lambova S; Muller-Ladner U
    Curr Rheumatol Rev; 2018; 14(2):108-116. PubMed ID: 28875826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting macrophage polarization as a promising therapeutic strategy for the treatment of osteoarthritis.
    Wang W; Chu Y; Zhang P; Liang Z; Fan Z; Guo X; Zhou G; Ren W
    Int Immunopharmacol; 2023 Mar; 116():109790. PubMed ID: 36736223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment.
    Jotanovic Z; Mihelic R; Sestan B; Dembic Z
    Curr Drug Targets; 2014 Jun; 15(6):635-61. PubMed ID: 24597569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation.
    Davies PS; Graham SM; MacFarlane RJ; Leonidou A; Mantalaris A; Tsiridis E
    Expert Opin Investig Drugs; 2013 Apr; 22(4):423-41. PubMed ID: 23409708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pain Management Strategies in Rheumatoid Arthritis: A Narrative Review.
    Sánchez-Flórez JC; Seija-Butnaru D; Valero EG; Acosta CDPA; Amaya S
    J Pain Palliat Care Pharmacother; 2021 Dec; 35(4):291-299. PubMed ID: 34623946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arthroscopic lavage and debridement for osteoarthritis of the knee: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(12):1-37. PubMed ID: 23074463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plain radiography or magnetic resonance imaging (MRI): Which is better in assessing outcome in clinical trials of disease-modifying osteoarthritis drugs? Summary of a debate held at the World Congress of Osteoarthritis 2014.
    Eckstein F; Le Graverand MP
    Semin Arthritis Rheum; 2015 Dec; 45(3):251-6. PubMed ID: 26142321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy and osteoarthritis.
    Brady SJ; Brooks P; Conaghan P; Kenyon LM
    Baillieres Clin Rheumatol; 1997 Nov; 11(4):749-68. PubMed ID: 9429735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects of Disease-Modifying Osteoarthritis Drugs.
    Oo WM
    Clin Geriatr Med; 2022 May; 38(2):397-432. PubMed ID: 35410687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.